From: Lower circulating endocannabinoid levels in children with autism spectrum disorder
Neurotypical control | Children with ASD | |
---|---|---|
N | 93 | 93 |
Age | 11.8 ± 4.3 | 13.1 ± 4.1^ |
% male | 79% | 79% |
BMI | 21.0 ± 4.2 | 20.4 ± 5.5 |
Epilepsy comorbidity | 0% | 10% |
High ASD symptoms severity | ||
ADOS comparison score = 8–10 | 77% | |
VABS standard score ≤ 70 | 88% | |
CARS total score ≥ 37 | 81% | |
SRS t scores ≥ 75 | 86% | |
Psychotropic medications* | ||
Any | 80% | |
Antipsychotic | 56% | |
SSRIs | 23% | |
Stimulants | 15% | |
Antiepileptic (mood stabilizers) | 13% | |
Benzodiazepines | 8% | |
Others | 5% |